Daiichi Sankyo Company Limited and Sarah Cannon Research Institute (Sarah Cannon) announced that the first patient has been dosed in the first-in-human phase 1 study evaluating DS-6000, a CDH6 directed antibody drug conjugate (ADC), in patients with advanced renal cell carcinoma or ovarian cancer with disease progression following standard treatment.
Despite recent advances in targeted treatment, five-year survival rates for both renal cell carcinoma and ovarian cancer remain low and new therapeutic strategies are needed for tumours that continue to progress on currently available medicines. CDH6 is a cadherin family protein overexpressed in several cancers, particularly renal cell and ovarian. CDH6 overexpression is associated with tumour growth and proliferation and has been correlated with poor prognosis in renal cell carcinoma. No CDH6 directed cancer therapies are currently approved.
“With DS-6000, we have applied our innovative DXd ADC technology to a promising molecular target, CDH6, and it has potential to serve as a new treatment modality for patients with renal cell or ovarian cancer,” said Arnaud Lesegretain, vice president oncology R&D and head, Alpha Portfolio, Daiichi Sankyo. “We are pleased to continue our successful collaboration with Sarah Cannon, working together on advancing the development of another novel ADC with first-in-class potential.”
DS-6000 is the sixth DXd ADC from the oncology pipeline of Daiichi Sankyo to enter clinical development and the third being developed in collaboration with Sarah Cannon Research Institute.
“We look forward to developing DS-6000 as a potential treatment option for people facing renal cell carcinoma or ovarian cancer,” says Erika Hamilton, MD, director, Breast Cancer and Gynecologic Cancer Research Program, Sarah Cannon Research Institute at Tennessee Oncology. “In partnership with Daiichi Sankyo, we will further evaluate whether DS-6000 may serve as a new and effective therapy for patients who have progressed on standard treatments.”
The two-part, multicenter, open-label, first-in-human phase 1 trial will evaluate the safety and efficacy of DS-6000 in adult patients with advanced renal cell carcinoma or ovarian cancer resistant or refractory to standard of care therapy.
The first part of the study (dose escalation) will assess the safety and tolerability of increasing doses of DS-6000 to determine the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) in approximately 46 patients with advanced renal cell carcinoma or ovarian tumors. The second part of the study (dose expansion) will further evaluate the safety and efficacy of DS-6000 at the RDE in two cohorts including approximately 30 patients with advanced renal cell carcinoma in cohort 1 and 25 patients with advanced ovarian cancer in cohort 2.
The study will evaluate safety endpoints including dose-limiting toxicities and adverse events and efficacy endpoints including overall response rate, duration of response, disease control rate, clinical benefit rate, time to response and progression-free survival. Pharmacokinetic and exploratory biomarker endpoints will also be assessed.
A total of approximately 102 patients are expected to be enrolled in this study at multiple sites in the US.
Renal cell carcinoma accounts for 90 percent of all kidney cancer. There were approximately 431,000 new cases of kidney cancer and over 179,000 deaths reported worldwide in 2020. Ovarian cancer is one of the three most common gynaecological malignancies. There were approximately 313,000 new cases of ovarian cancer and over 207,000 deaths reported worldwide in 2020. The five-year survival rate is 13 percent and 30 percent, respectively, for patients diagnosed with metastatic renal cell carcinoma and ovarian cancer.
DS-6000 is a potential first-in-class CDH6 directed antibody drug conjugate (ADC). Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-6000 is the sixth ADC in the Daiichi Sankyo oncology pipeline to enter clinical development.
DS-6000 is comprised of a humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a tetrapeptide-based cleavable linker. Preclinical research shows that DS-6000 binds to CDH6 on the surface of cancer cells, and it is proposed that DS-6000 is then brought inside the cell where lysosomal enzymes break down the linker and release the DXd payload to destroy the cell. In preclinical studies, DS-6000 inhibited tumour growth and induced tumour regression in CDH6 expressing renal cell and ovarian tumours
